Science 37 (SNCE) CEO On Stock Beginning Trading On The Nasdaq Today

<p>Science 37 (SNCE) is an American clinical research company that specializes in Decentralized Clinical Trials. CEO David Coman weighs in on the stock beginning to trade today on the Nasdaq after a SPAC deal with LifeSci Acquisition II Corp. Approximately $235M net cash was received in the deal. How will the stock continue to perform and what is next for the now public company?</p>